New Roche breast cancer drug wins backing in Europe and Japan
LONDON (Reuters) - Roche's new breast cancer drug Kadcyla was approved in Japan on Friday and recommended for approval in Europe, building on February's United States green light for the product.
Kadcyla is designed for patients with late-stage disease whose cancer cells contain increased amounts of a protein known as HER2.
It works by attaching Herceptin to a drug called DM1, developed by ImmunoGen, which interferes with cancer cell growth. ImmunoGen will receive a US$5 million (S$6.23 million) milestone payment from Roche following the Japanese approval.
The European Medicines Agency (EMA) said on Friday its experts had also recommended a prostate cancer medicine, Xofigo, from Algeta and Bayer, which is also already approved in the United States.